{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:22Z","timestamp":1790409262158,"version":"4.1.0"},"reference-count":114,"publisher":"Informa UK Limited","issue":"7-8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/13543784.2025.2532446","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T13:03:06Z","timestamp":1752498186000},"page":"571-589","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions"],"prefix":"10.1080","volume":"34","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O\u2019Gorman","sequence":"additional","affiliation":[{"name":"The Mater Misericordiae University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Leypoldt","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"University of Poitiers, CHU & Inserm","place":["Poitiers, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"University Hospital and INSERM UMR-S1277","place":["Lille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital H\u00f4tel Dieu","place":["Nantes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens","place":["Athens, Greece"]},{"name":"University of Korea","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Heidelberg University","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[{"name":"Heidelberg University","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Hospital Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Tennessee Oncology","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksa\u00e7","sequence":"additional","affiliation":[{"name":"Istinye University","place":["Ankara, Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, UPS","place":["Toulouse, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center","place":["Phoenix, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X"},{"key":"e_1_3_7_4_1","unstructured":"Global Cancer Observatory. Globocan. Multiple myeloma. 2022 [cited 2024 Oct 28]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/35-multiple-myeloma-fact-sheet.pdf"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_7_6_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Multiple myeloma; version 1. 2025 [cited 2024 Oct 18]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1359105318772073"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017635"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.12.001"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193864"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00797-8"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00070-X"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026230"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284325"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00148-0"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02266"},{"key":"e_1_3_7_28_1","unstructured":"Sanofi-Aventis U.S. LLC. Sarclisa (isatuximab-irfc) prescribing information. 2024 Sep [cited 2024 Oct 20]. Available from: https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf"},{"key":"e_1_3_7_29_1","unstructured":"European Medicines Agency. Sarclisa INN-Isatuximab. Summary of product characteristics. 2024 Jul 29 [cited 2024 Oct 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf"},{"key":"e_1_3_7_30_1","unstructured":"Sarclisa (isatuximab) package insert. Nishi Shinjuku. Tokyo: Sanofi Col Ltd.; 2021 (in Japanese). [cited 2024 Oct 20]. Available from: https:\/\/www.pmda.go.jp\/drugs\/2021\/P20211111001\/780069000_30200AMX00511000_A100_1.pdf"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0536-3"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02138-4"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008735"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_7_41_1","unstructured":"Food & Drug Administration - Center for Drug Evaluation and Research. April 12 2024 Meeting of the oncologic drugs advisory committee (ODAC) webcast - part 2. 2024 Apr 12 [cited 2024 Oct 24]. Available from: https:\/\/www.fda.gov\/media\/177651\/download"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02347-4"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203818"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207087"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7500"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282521"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099341"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01894-9"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936-7"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00905-8"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.739"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174972"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186834"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179866"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01045-3"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023597"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.419"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.197"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0119-4"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01431-x"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02255-9"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1841747"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_7_77_1","volume-title":"Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting","author":"Vesole DH","year":"1982","unstructured":"Vesole DH, Martin TG, Trudel S, et al. Phase II study of isatuximab, and weekly carfilzomib + dexamethasone in relapsed and refractory multiple myeloma (RRMM). In: Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting; San Diego (CA). 1982 [2024 Dec 7\u201310]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper209597.html"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14225"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01590-7"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200165"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104353"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107324"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac574"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.004"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S442692"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000829"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70041"},{"key":"e_1_3_7_89_1","unstructured":"Phase 1\u20132 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) \u2013 master protocol. [cited 2024 Oct 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04643002"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8025"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284730"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01924-9"},{"key":"e_1_3_7_93_1","unstructured":"A randomized phase 2 open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma (RRMM). [cited 2024 Oct 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704049"},{"key":"e_1_3_7_94_1","unstructured":"A study to investigate subcutaneous isatuximab in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma (SubQSA). [cited 2024 Oct 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06356571"},{"key":"e_1_3_7_95_1","unstructured":"Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma. [cited 2024 Oct 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05889221"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00744"},{"key":"e_1_3_7_97_1","unstructured":"Lenalidomide bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma. [cited 2024 Oct 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05804032"},{"key":"e_1_3_7_98_1","unstructured":"Iberdomide vs. Iberdomide plus isatuximab maintenance therapy post ASCT in newly diagnosed multiple myeloma. [cited 2025 Mar 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06216158"},{"key":"e_1_3_7_99_1","volume-title":"Poster presented at: 21st Annual Meeting of the International Myeloma Society","author":"S\u00e1nchez Avello N","year":"2024","unstructured":"S\u00e1nchez Avello N, Calvo Pajares P, Cordero P, et al. P-418 subcutaneous administration of isatuximab by an on-body delivery system (OBDS) in multiple myeloma patients: results of a nurse survey. In: Poster presented at: 21st Annual Meeting of the International Myeloma Society; Brazil. Rio de Janiero; 2024 Sep 25\u201328. Available from: https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/10\/IMSAnnual2024Abstracts.pdf"},{"key":"e_1_3_7_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0868-z"},{"key":"e_1_3_7_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3258"},{"key":"e_1_3_7_102_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660"},{"key":"e_1_3_7_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970628.27700.c7"},{"key":"e_1_3_7_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26319"},{"key":"e_1_3_7_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26602"},{"key":"e_1_3_7_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106576"},{"key":"e_1_3_7_107_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_7_108_1","first-page":"1","article-title":"Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future","volume":"22","author":"Zanwar S","year":"2024","unstructured":"Zanwar S, Kumar S. Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. Leuk Lymphoma. 2024 Dec;22:1\u201311.","journal-title":"Leuk Lymphoma"},{"key":"e_1_3_7_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16292"},{"key":"e_1_3_7_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439"},{"key":"e_1_3_7_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106948"},{"key":"e_1_3_7_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01051-x"},{"key":"e_1_3_7_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02264-3"},{"key":"e_1_3_7_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157302"},{"key":"e_1_3_7_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_7_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1729734"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2532446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T08:03:03Z","timestamp":1754640183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2532446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":114,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/13543784.2025.2532446"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2532446","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}